🔴 Context Therapeutics is trading 5.1% down today with no clear company-specific catalyst

Context Therapeutics is trading 5.1% down at $0.35, with no clear company-specific catalyst identified.

• No credible company-specific announcement dated September 25, 2026, was identified.
• The latest located update was the September 9 announcement that the first patient entered the CT-202 Phase 1 trial; it is stale and not a clear catalyst for the decline.
• Broader markets were higher, so the move does not clearly track overall market direction.